Literature DB >> 22841018

Correlation between prostate brachytherapy-related urethral stricture and peri-apical urethral dosimetry: a matched case-control study.

James J Earley1, Ather M Abdelbaky, Melanie J Cunningham, Eliot Chadwick, Stephen E M Langley, Robert W Laing.   

Abstract

BACKGROUND AND
PURPOSE: Radiation dose to the bulbomembranous urethra has been shown to correlate with urethral stricture formation. This retrospective case-control study was designed to explore the relationship between dose to the apical/peri-apical regions of the urethra and development of brachytherapy (BXT)-related urethral stricture.
MATERIALS AND METHODS: Cases were patients who developed urethral stricture after treatment with BXT as monotherapy and who had urethral dosimetry post-implant. Each case was matched with a control that had not developed urethral stricture. Dosimetry was compared between cases and controls.
RESULTS: Twenty-three cases were pair matched with 23 controls. There were no significant differences between the two groups in terms of age, presenting Prostate Specific Antigen (PSA), International Prostate Symptom Score (IPSS) or Gleason score. The dose delivered to the peri-apical and apical urethra was significantly higher for cases when compared with controls (peri-apical urethra: mean V(150) 1.1 Vs 0.8 cc [p=0.02]; apical urethra: mean dose 200 Vs 174 Gy [p=0.01]). The distance from the prostate apex to isodose lines was also found to be significant in predicting stricture formation.
CONCLUSION: There was evidence to suggest that the development of BXT-related stricture was associated with radiation dose at the apical and peri-apical urethra. Attention to the dose delivered to those areas may minimise the risk of developing such morbidity.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22841018     DOI: 10.1016/j.radonc.2012.06.001

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  3 in total

1.  Intraluminal urethral brachytherapy for recurrence of transitional cell carcinoma of urinary bladder in urethral stump.

Authors:  Bikramjit Chakrabarti; Suman Ghorai; Somapriya Basu Ray; Sanjay Kumar Kar
Journal:  J Contemp Brachytherapy       Date:  2013-03-29

2.  Long term outcome and side effects in patients receiving low-dose I125 brachytherapy: a retrospective analysis.

Authors:  Pieter Logghe; Rolf Verlinde; Frank Bouttens; Caroline Van den Broecke; Nathalie Deman; Koen Verboven; Dirk Maes; Luc Merckx
Journal:  Int Braz J Urol       Date:  2016 Sep-Oct       Impact factor: 1.541

3.  Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer.

Authors:  Kenta Onishi; Nobumichi Tanaka; Makito Miyake; Yasushi Nakai; Satoshi Anai; Kazumasa Torimoto; Kaori Yamaki; Isao Asakawa; Masatoshi Hasegawa; Tomomi Fujii; Noboru Konishi; Kiyohide Fujimoto
Journal:  Clin Transl Radiat Oncol       Date:  2018-11-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.